When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
While a 2016 study found no significant difference in infection rates between using traditional sutures versus staples, at least one research team feels the surgical staple has room…
F. Perry Wilson, MD, MSCE, shares insights from a review of recent study results published in the New England Journal of Medicine examining duty-hours rules at 63 residency…
Pharmacomechanical thrombolysis can be particularly effective in mitigating post-thrombotic syndrome (PTS) in younger patients, as demonstrated by data from the ATTRACT trial.
